Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19

M. Hoffmann, S. Schroeder, H. Kleine-Weber, M. Müller, C. Drosten, S. Pöhlmann,

2021

https://doi.org/10.1128/AAC.00754-20

Цитирование

Об авторах

M. Hoffmann
Deutsches Primatenzentrum - Leibniz Institute for Primate Research, Göttingen, Germany
S. Schroeder
Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany
H. Kleine-Weber
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany
M. Müller
Berlin Institute of Health, Institute of Virology, Berlin, Germany
C. Drosten
German Centre for Infection Research, Associated Partner Charité, Berlin, Germany
S. Pöhlmann
Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov University, Moscow, Russian Federation

Название журнала

Том

Выпуск

Страницы

Ключевые слова

camostat mesilate; nafamstat mesilate; virus spike protein; vitronectin; dipeptidyl carboxypeptidase; guanidine derivative; nafamstat; proteinase inhibitor; antiviral activity; Article; cell viability; coronavirus disease 2019; drug indication; drug safety; EC50; host cell; human; nonhuman; priority journal; Severe acute respiratory syndrome coronavirus 2; Betacoronavirus; Coronavirus infection; pandemic; SARS coronavirus; virus entry; virus pneumonia; Betacoronavirus; Coronavirus Infections; Guanidines; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Protease Inhibitors; SARS Virus; Virus Internalization

Издатель

Тип документа

Источник